Background: Gliomas are the most common primary tumours of the central nervous system. Despite a multimodal therapeutic approach combining surgery, radiotherapy, and temozolomide (TMZ), treatment remains highly challenging, and the prognosis is poor. One of the potential molecular targets that may improve therapeutic outcomes is the purinergic receptor P2X7 (P2X7R).Methods: The aim of this systematic review was to summarize current knowledge on the expression, functionality, and therapeutic relevance of P2X7R in gliomas. A comprehensive literature search was conducted in three databases (PubMed, Scopus, and Web of Science) up to 12 April 2025. Original in vitro and in vivo studies evaluating P2X7R in glioma models were included.Results:A total of 41 studies met the inclusion criteria and were analyzed. For each included study, the risk of bias was assessed using the OHAT Risk of Bias Tool. The review protocol was registered in PROSPERO. Although individual studies differed in methodology and outcomes, the majority reported that P2X7R modulation affected glioma cell behaviour, including proliferation, survival, migration, immune signalling, and response to treatment. Due to the heterogeneity of models and endpoints, a narrative synthesis was performed.Conclusions:Overall, current evidence suggests that P2X7R may represent a biologically relevant and pharmacologically actionable target in gliomas, although further high-quality studies are required to confirm its clinical potential.
背景：胶质瘤是中枢神经系统最常见的原发性肿瘤。尽管采用手术、放疗和替莫唑胺（TMZ）相结合的多模式治疗方法，治疗仍极具挑战性且预后不良。嘌呤能受体P2X7（P2X7R）是可能改善治疗效果的潜在分子靶点之一。 方法：本系统综述旨在总结目前关于P2X7R在胶质瘤中的表达、功能及治疗相关性的认识。截至2025年4月12日，我们在三个数据库（PubMed、Scopus和Web of Science）中进行了全面的文献检索。纳入在胶质瘤模型中评估P2X7R的原始体外和体内研究。 结果：共有41项研究符合纳入标准并进行分析。对每项纳入研究，使用OHAT偏倚风险评估工具评估其偏倚风险。综述方案已在PROSPERO注册。尽管各项研究在方法和结果上存在差异，但多数报告表明P2X7R调节影响胶质瘤细胞行为，包括增殖、存活、迁移、免疫信号传导及治疗反应。由于模型和终点的异质性，我们进行了叙述性综合。 结论：总体而言，现有证据表明P2X7R可能代表胶质瘤中一个具有生物学相关性且可药用的靶点，但仍需进一步高质量研究来确认其临床潜力。
肿瘤(癌症)患者之家